Catheter-Related Bloodstream Infection Market Report 2024

The catheter-related bloodstream infection market size has grown strongly in recent years. It will grow from $1.44 billion in 2023 to $1.53 billion in 2024 at a compound annual growth rate (CAGR) of 5.9%. The growth observed in the historic period can be attributed to several key factors, an increase in the incidence of chronic diseases, heightened awareness and education regarding healthcare, a rise in hospital-acquired infections, the growing elderly population, and the implementation of enhanced infection control programs in hospitals and healthcare settings.

The catheter-related bloodstream infection market size is expected to see strong growth in the next few years. It will grow to $1.93 billion in 2028 at a compound annual growth rate (CAGR) of 6.1%. In the forecast period, growth can be attributed to several factors, the increasing prevalence of healthcare-associated infections (HAIs), heightened awareness and training on infection control practices, expansion of healthcare infrastructure, a growing geriatric population, and supportive government policies and initiatives. Major trends anticipated during this period include innovations in biomaterials, advancements in smart catheter technology, the development of more effective catheter lock solutions with advanced antimicrobial properties, innovations in catheter sterilization processes, and the introduction of automated flushing systems.

The increasing incidence of hospital-acquired infections is anticipated to drive growth in the market for catheter-related bloodstream infections in the future. Hospital-acquired infections (HAIs) are infections that patients contract while undergoing treatment for other conditions in healthcare settings, typically emerging 48 hours or more after admission. Factors contributing to the rise in hospital-acquired infections include antimicrobial resistance, inadequate infection control protocols, and patient vulnerability. Catheter-related bloodstream infections are particularly problematic within HAIs due to the invasive nature of catheters and their potential for microbial colonization, posing risks to patients with indwelling catheters. For example, the National Library of Medicine reported in January 2023 that the global healthcare-associated infection (HAI) rate was 0.14%, with an annual increase of 0.06%. Hence, the escalating prevalence of hospital-acquired infections is set to propel growth in the catheter-related bloodstream infection market.

Leading companies in the catheter-related bloodstream infection market are focusing on developing innovative solutions such as catheter lock therapies to enhance infection prevention and improve patient outcomes. A catheter lock solution involves instilling a liquid into a catheter to prevent infections and maintain catheter patency between uses. For instance, in November 2023, CorMedix Inc., a US-based biopharmaceutical firm specializing in therapeutic products, received FDA approval for DefenCath (taurolidine and heparin) catheter lock solution. This solution is tailored for adult patients with kidney failure undergoing chronic hemodialysis through central venous catheters (CVCs), combining heparin for anticoagulation with taurolidine's broad-spectrum antimicrobial properties to reduce catheter-related bloodstream infections (CRBSIs).

In April 2022, CEMMA Medical Company Limited, based in Taiwan, partnered with LipoCoat BV to develop a coated central venous catheter (CVC) aimed at sustainable infection control. This collaboration leverages CEMMA's expertise in catheter technology and LipoCoat's bio-inspired coating technology, aiming to deliver an advanced CVC solution to combat the global challenge of healthcare-associated infections. LipoCoat BV, headquartered in the Netherlands, specializes in bio-inspired coating technologies.

Major companies operating in the catheter-related bloodstream infection market are Pfizer Inc., Johnson & Johnson Services Inc., Novartis AG, 3M Company, Eli Lilly and Company, Fresenius Medical Care AG & Co. KGaA, Becton Dickinson and Company, Viatris Inc., B. Braun Medical Inc., Aurobindo Pharma Limited, Lupin Ltd., Xellia Pharmaceuticals Ltd., SteriMax Inc., Geistlich Pharma AG, Bactiguard AB, Hetero Healthcare Ltd., TauroPharm GmbH, Advacare Pharma, Citus Pharmaceuticals Inc., CorMedix Inc., JoinHub Pharma LLP, IntegraDose Compounding Services LLC.

North America was the largest region in the catheter-related bloodstream infection market in 2023. The regions covered in the catheter-related bloodstream infection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the catheter-related bloodstream infection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Catheter-related bloodstream infection (CRBSI) is a serious healthcare-associated infection caused by bacteria or fungi entering the bloodstream through a catheter - a tube used to administer medications or nutrients directly into a vein. This condition can lead to sepsis and other severe complications, emphasizing the critical need for prompt diagnosis and treatment.

The primary treatments for CRBSI include antibiotic lock therapy and antimicrobial agents. Antibiotic lock therapy involves infusing a concentrated antibiotic solution into the catheter lumen, where it remains for an extended period to prevent or eliminate catheter-related infections locally, without systemic administration. This approach is frequently employed in patients with central venous catheters to manage and prevent CRBSI. Common sources of infection and causative agents include Staphylococcus aureus, Acinetobacter baumannii, Escherichia coli (E. coli), Klebsiella pneumoniae (K. pneumoniae), Candida species, Pseudomonas aeruginosa, among others. These treatments are available through hospital pharmacies, retail pharmacies, and online pharmacies.

The catheter-related bloodstream infection research report is one of a series of new reports that provides catheter-related bloodstream infection market statistics, including the catheter-related bloodstream infection industry's global market size, regional shares, competitors with a catheter-related bloodstream infection market share, detailed catheter-related bloodstream infection market segments, market trends and opportunities, and any further data you may need to thrive in the catheter-related bloodstream infection industry. This catheter-related bloodstream infection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The catheter-related bloodstream infection market consists of revenues earned by entities by providing services such as blood culture testing, catheter flushing and maintenance, aseptic catheter insertion, hand hygiene training, and compliance monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The catheter-related bloodstream infection market also includes sales of catheters, catheter insertion kits, catheter maintenance equipment, monitoring and diagnostic devices, and infection control equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.